Provided by Tiger Trade Technology Pte. Ltd.

Tredegar

7.69
-0.1100-1.41%
Post-market: 7.690.00000.00%19:30 EDT
Volume:120.85K
Turnover:929.21K
Market Cap:268.46M
PE:8.03
High:7.80
Open:7.74
Low:7.64
Close:7.80
52wk High:10.53
52wk Low:6.25
Shares:34.91M
Float Shares:28.20M
Volume Ratio:0.91
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9572
EPS(LYR):0.9604
ROE:15.47%
ROA:6.50%
PB:1.17
PE(LYR):8.01

Loading ...

Medallion Metals strikes profit-share processing deal with TG Metals

TIPRANKS
·
Jul 22

Analyst Tara Bancroft Raises TG Therapeutics Price Target to $75 on Strong Long-Term Briumvi Growth Outlook

TIPRANKS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), McKesson (MCK) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 22

TG Therapeutics Targets Myasthenia Gravis Growth With New BRIUMVI Trial

TIPRANKS
·
Jul 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Jul 16

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 14

TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jul 13

TG Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 13

TG Metals Drilling Expands Laterite Gold Potential at Van Uden

TIPRANKS
·
Jul 09

Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says

MT Newswires Live
·
Jul 07

BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating

MT Newswires Live
·
Jul 07

TG Therapeutics price target raised to $20 from $17 at BofA

TIPRANKS
·
Jul 07

TG Therapeutics Price Target Maintained with a $70.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 07

TG Therapeutics: Buy Rating Reaffirmed as Briumvi Schizophrenia Trial Adds Upside Optionality; $70 Price Target Unchanged

TIPRANKS
·
Jul 06

TG Therapeutics initiates Briumvi clinical trial

TIPRANKS
·
Jul 06

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

GlobeNewswire
·
Jul 01

TG Therapeutics (TGTX) Gains Momentum As The Fair Value Narrative Turns More Cautious

Simply Wall St.
·
Jun 26

TG Jones backs down from clash with landlords in bid to save stores

cityam
·
Jun 23

TG Therapeutics price target raised to $83 from $57 at Jefferies

TIPRANKS
·
Jun 23

Jefferies Reaffirms Their Buy Rating on TG Therapeutics (TGTX)

TIPRANKS
·
Jun 22